Abstract The mitogen-activated protein (MAP) cascade leading to the activation of extracellular signal-regulated kinases 1/2 (ERK1/2) is critical for regulating myeloma cell growth; however, the relationship of ERK1/2 activity with vascular endothelial growth factor (VEGF) production and the effects of its downmodulation in myeloma cells are not elucidated. We found that the treatment with MAP/ERK kinase 1 (MEK1) inhibitors PD98059 or PD184352 produced a reduction of phosphorylated ERK1/2 (p-ERK1/2) levels in myeloma cells of more than 80% and prevented the increase of p-ERK1/2 induced by interleukin-6 (IL-6). MEK1 inhibitors also induced a significant inhibition of myeloma cell proliferation and blunted the stimulatory effect induced by IL-6. A significant inhibition of basal VEGF secretion by myeloma cells as well as a suppression of the stimulatory effect of IL-6 on VEGF was observed by either PD98059 or PD184352. Moreover, we also found that the PI3K kinase inhibitors, but not p38 MAPK inhibitors, reduced VEGF secretion by myeloma cells and increase the inhibitory effect of MEK1 inhibitors. In an ‘in vitro’ model of angiogenesis, we found that MEK1 inhibitors impair vessel formation induced by myeloma cells and restored by VEGF treatment, suggesting that the downmodulation of ERK1/2 activity reduces myelomainduced angiogenesis by inhibiting VEGF secretion. Leukemia (2004) 18, 628–635. doi:10.1038/sj.leu.2403269 Published online 22 January 2004 Keywords: signal transduction; molecular targets for therapy; ERK downmodulation; myeloma; VEGF; angiogenesis

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis / Giuliani, N; Lunghi, P; Morandi, F; Colla, S; Bonomini, S; Hojden, M; Rizzoli, V; Bonati, A. - In: LEUKEMIA. - ISSN 0887-6924. - 18(2004), pp. 628-635. [10.1038/sj.leu.2403269]

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis

GIULIANI, Nicola;LUNGHI, Paolo;COLLA, Simona;RIZZOLI, Vittorio;BONATI, Antonio
2004

Abstract

Abstract The mitogen-activated protein (MAP) cascade leading to the activation of extracellular signal-regulated kinases 1/2 (ERK1/2) is critical for regulating myeloma cell growth; however, the relationship of ERK1/2 activity with vascular endothelial growth factor (VEGF) production and the effects of its downmodulation in myeloma cells are not elucidated. We found that the treatment with MAP/ERK kinase 1 (MEK1) inhibitors PD98059 or PD184352 produced a reduction of phosphorylated ERK1/2 (p-ERK1/2) levels in myeloma cells of more than 80% and prevented the increase of p-ERK1/2 induced by interleukin-6 (IL-6). MEK1 inhibitors also induced a significant inhibition of myeloma cell proliferation and blunted the stimulatory effect induced by IL-6. A significant inhibition of basal VEGF secretion by myeloma cells as well as a suppression of the stimulatory effect of IL-6 on VEGF was observed by either PD98059 or PD184352. Moreover, we also found that the PI3K kinase inhibitors, but not p38 MAPK inhibitors, reduced VEGF secretion by myeloma cells and increase the inhibitory effect of MEK1 inhibitors. In an ‘in vitro’ model of angiogenesis, we found that MEK1 inhibitors impair vessel formation induced by myeloma cells and restored by VEGF treatment, suggesting that the downmodulation of ERK1/2 activity reduces myelomainduced angiogenesis by inhibiting VEGF secretion. Leukemia (2004) 18, 628–635. doi:10.1038/sj.leu.2403269 Published online 22 January 2004 Keywords: signal transduction; molecular targets for therapy; ERK downmodulation; myeloma; VEGF; angiogenesis
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis / Giuliani, N; Lunghi, P; Morandi, F; Colla, S; Bonomini, S; Hojden, M; Rizzoli, V; Bonati, A. - In: LEUKEMIA. - ISSN 0887-6924. - 18(2004), pp. 628-635. [10.1038/sj.leu.2403269]
File in questo prodotto:
File Dimensione Formato  
MYELOMA-Leukemia.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 313.79 kB
Formato Adobe PDF
313.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2298625
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 67
social impact